PUBLISHER: DelveInsight | PRODUCT CODE: 1108665
PUBLISHER: DelveInsight | PRODUCT CODE: 1108665
DelveInsight's, 'Wilson's Disease (WD) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of Wilson's disease (WD) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Wilson's disease (WD): Disease Understanding
Wilson's disease (WD) Overview
According to the European Association for the study of the Liver (EASL), Wilson's disease (WD) is an inherited disorder in which defective biliary excretion of copper leads to its accumulation, particularly in the liver and brain.
The disease is progressive and, if left untreated, may cause liver (hepatic) disease, central nervous system dysfunction, and death. Early diagnosis and treatment may prevent serious long-term disability and life-threatening complications. The features of this condition include a combination of liver disease and neurological and psychiatric problems. Liver disease is typically the initial feature of WD in affected children and young adults; individuals diagnosed at an older age usually do not have symptoms of liver problems, although they may have very mild liver disease. The signs and symptoms of liver disease include yellowing of the skin or whites of the eyes (jaundice), fatigue, loss of appetite, and abdominal swelling. Nervous system or psychiatric problems are often the initial features in individuals diagnosed in adulthood and commonly occur in young adults with WD. Signs and symptoms of these problems can include clumsiness, tremors, difficulty walking, speech problems, impaired thinking ability, depression, anxiety, and mood swings. A mutation in the ATP7B gene, which codes for copper transportation, causes WD. A person must inherit the gene from both parents to have WD.
According to the National Organization of Rare Diseases, WD is a disorder that affects males and females in equal numbers. The disease is found in all races and ethnic groups. Although estimates vary, it is believed that WD occurs in approximately one in 30,000-40,000 people worldwide. Approximately 1 in 90 people may be carriers of the disease gene. Although only about 2,000-3,000 cases have been diagnosed in the United States, other affected individuals may be misdiagnosed with neurological, liver, or psychiatric disorders. According to one estimate, there may be 9,000 people affected by WD in the United States.
WD can affect many different systems of the body. Affected people often develop signs and symptoms of chronic liver disease in their teenage years or early twenties. These features may include jaundice; abnormal fluid retention, which can lead to swelling of the legs and/or abdomen; weight loss; nausea and vomiting, and/or fatigue. Unfortunately, some people may not experience any signs until they suddenly develop acute liver failure.
Affected people often experience a variety of neurologic (central nervous system-related) signs and symptoms, as well. Neurologic features often develop after the liver has retained a significant amount of copper; however, they have been seen in people with little to no liver damage. These symptoms may include tremors, muscle stiffness, and problems with speech, swallowing, and/or physical coordination. Almost all people with neurologic symptoms have Kayser-Fleisher rings - a rusty brown ring around the cornea of the eye that can best be viewed using an ophthalmologist's slit lamp.
Treatment for WD is life-long and aimed at lowering copper levels to nontoxic levels, and at preventing the progression of the disease, and trying to reverse any signs and symptoms that have appeared because of copper accumulation in the body. Treatment may be divided into three parts: first, treatment of symptomatic patients; second, maintenance therapy after the copper has been reduced in affected tissues; and third, in asymptomatic patients, maintenance therapy may be used from the beginning.
The several promising novel therapies, including chelators targeting specific cell types and cell-based and gene therapies, may revolutionize the care for WD patients. However, timely clinical diagnosis remains the main challenge, and many unmet needs exist because of possible clinical deterioration in treated patients.
The Wilson's disease (WD) epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted Wilson's disease (WD) epidemiology segmented as the prevalent cases of Wilson's disease, diagnosed cases of Wilson's disease, prevalent cases of Wilson's disease based on clinical manifestation, and prevalent cases of Wilson's disease based on symptoms. The report includes the prevalent scenario of Wilson's disease (WD) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides Wilson's disease (WD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent patient population of Wilson's disease (WD) in the 7MM countries comprised about 37,000 cases in 2021.
As per the estimates, Japan had the highest total prevalent patient population of Wilson's disease (WD) population in 2021. Among the EU5 countries, Germany had the highest total prevalent patient population of Wilson's disease (WD) with ~3,000 cases, followed by France in 2021. On the other hand, Spain had the lowest total prevalent patient population of Wilson's disease (WD), close to 750 cases in 2021.
KOL Views
We interview KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.
Key Questions Answered
Wilson's disease (WD) Epidemiology report will allow the user to:
Geographies Covered
Study Period: 2019-2032